Ignite Creation Date:
2024-05-06 @ 12:41 AM
Last Modification Date:
2024-10-26 @ 10:53 AM
Study NCT ID:
NCT01637597
Status:
UNKNOWN
Last Update Posted:
2016-07-21
First Post:
2012-06-28
Brief Title:
Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation
Sponsor:
Organization:
National Taiwan University Hospital
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
Blood and tumor tissue are being collected during the course of this study to assess the safety and tolerability and spectrum of side effects of the study drug However it is possible that after completion of all study-related analyses some volume of samples may remain These left-over samples could be a valuable resource for future research
Before any left-over samples can be used for any research other than that specified in the protocol patient must sign an additional future use consent from indicating they give their permission for these samples to be used in future research By signing the main consent form patients are only giving their permission to use their samples for the study related procedures
Enrollment Count:
12
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
Time Perspective List:
Who Masked List: